PharmaCorp Rx Inc.
PharmaCorp Rx Inc. operates retail pharmacies under the PharmaChoice name in Canada. It offers prescription drug and custom compounding specialization services; weight loss and lifestyle management solutions, including health and wellness products; and convenience and confectionary products. The company was incorporated in 2021 and is headquartered in Saskatoon, Canada.
PharmaCorp Rx Inc. (PCRX) - Total Assets
Latest total assets as of September 2025: CA$39.71 Million CAD
Based on the latest financial reports, PharmaCorp Rx Inc. (PCRX) holds total assets worth CA$39.71 Million CAD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
PharmaCorp Rx Inc. - Total Assets Trend (2021–2024)
This chart illustrates how PharmaCorp Rx Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
PharmaCorp Rx Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
PharmaCorp Rx Inc.'s total assets of CA$39.71 Million consist of 41.4% current assets and 58.6% non-current assets.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 36.6% |
| Accounts Receivable | CA$326.78K | 0.9% |
| Inventory | CA$1.31 Million | 3.7% |
| Property, Plant & Equipment | CA$0.00 | 0.0% |
| Intangible Assets | CA$5.13 Million | 14.6% |
| Goodwill | CA$11.48 Million | 32.6% |
Asset Composition Trend (2021–2024)
This chart illustrates how PharmaCorp Rx Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: PharmaCorp Rx Inc.'s current assets represent 41.4% of total assets in 2024, a decrease from 100.0% in 2021.
- Cash Position: Cash and equivalents constituted 36.6% of total assets in 2024, down from 98.0% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 46.0% of total assets, an increase from 0.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 32.6% of total assets.
PharmaCorp Rx Inc. Competitors by Total Assets
Key competitors of PharmaCorp Rx Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Cachet Pharmaceutical Co Ltd
SHE:002462
|
China | CN¥12.68 Billion |
|
Yunnan Hongxiang Yixintang
SHE:002727
|
China | CN¥15.84 Billion |
|
Luyan Pharma Co Ltd
SHE:002788
|
China | CN¥13.04 Billion |
|
Ji Yao Holding Group Co Ltd
SHE:300108
|
China | CN¥1.43 Billion |
|
Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd.
SHE:300937
|
China | CN¥1.75 Billion |
|
ShuYu Civilian Pharmacy Corp. Ltd.
SHE:301017
|
China | CN¥9.84 Billion |
|
Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd
SHE:301126
|
China | CN¥6.56 Billion |
|
Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A
SHE:301408
|
China | CN¥5.26 Billion |
PharmaCorp Rx Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - PharmaCorp Rx Inc. generates 0.16x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - PharmaCorp Rx Inc. is currently not profitable relative to its asset base.
PharmaCorp Rx Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.53 | 42.62 | 33.16 |
| Quick Ratio | 1.79 | 42.10 | 33.08 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CA$5.12 Million | CA$ 26.65 Million | CA$ 21.29 Million |
PharmaCorp Rx Inc. - Advanced Valuation Insights
This section examines the relationship between PharmaCorp Rx Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.73 |
| Latest Market Cap to Assets Ratio | 0.88 |
| Asset Growth Rate (YoY) | 1417.3% |
| Total Assets | CA$35.21 Million |
| Market Capitalization | $31.02 Million USD |
Valuation Analysis
Near Book Valuation: The market values PharmaCorp Rx Inc.'s assets close to their book value ( 0.88x), suggesting investors view the company's assets at approximately fair value.
Rapid Asset Growth: PharmaCorp Rx Inc.'s assets grew by 1417.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for PharmaCorp Rx Inc. (2021–2024)
The table below shows the annual total assets of PharmaCorp Rx Inc. from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CA$35.21 Million | +1417.30% |
| 2023-12-31 | CA$2.32 Million | -15.10% |
| 2022-12-31 | CA$2.73 Million | +173.19% |
| 2021-12-31 | CA$1.00 Million | -- |